Hohimer Wealth Management LLC Invests $339,000 in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Hohimer Wealth Management LLC bought a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the 3rd quarter, Holdings Channel reports. The institutional investor bought 6,994 shares of the company’s stock, valued at approximately $339,000.

Several other hedge funds also recently added to or reduced their stakes in AMPH. Victory Capital Management Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 10.9% in the 3rd quarter. Victory Capital Management Inc. now owns 218,531 shares of the company’s stock valued at $10,605,000 after purchasing an additional 21,530 shares during the last quarter. International Assets Investment Management LLC purchased a new stake in Amphastar Pharmaceuticals in the third quarter valued at approximately $11,070,000. Intech Investment Management LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the second quarter valued at approximately $426,000. Los Angeles Capital Management LLC purchased a new position in shares of Amphastar Pharmaceuticals during the third quarter worth approximately $785,000. Finally, Glenmede Trust Co. NA grew its position in shares of Amphastar Pharmaceuticals by 145.3% during the third quarter. Glenmede Trust Co. NA now owns 37,884 shares of the company’s stock worth $1,839,000 after acquiring an additional 22,439 shares during the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

AMPH has been the subject of a number of recent research reports. Wells Fargo & Company began coverage on shares of Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They set an “equal weight” rating and a $55.00 price target for the company. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $60.33.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ AMPH opened at $43.64 on Wednesday. The stock has a fifty day moving average price of $47.32 and a 200 day moving average price of $44.63. Amphastar Pharmaceuticals, Inc. has a 1-year low of $36.56 and a 1-year high of $65.92. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The company has a market cap of $2.10 billion, a PE ratio of 14.55, a P/E/G ratio of 0.87 and a beta of 0.78.

Insider Transactions at Amphastar Pharmaceuticals

In related news, Director Richard K. Prins sold 5,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $48.80, for a total value of $244,000.00. Following the sale, the director now directly owns 31,471 shares in the company, valued at $1,535,784.80. The trade was a 13.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Yakob Liawatidewi sold 5,214 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total value of $271,388.70. Following the completion of the transaction, the executive vice president now owns 74,938 shares of the company’s stock, valued at $3,900,522.90. The trade was a 6.51 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 24,533 shares of company stock worth $1,238,842. Company insiders own 27.10% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.